top of page
News, Events and Updates
Search
Chronic Treatment with the Tetrahydrofuran Derivative ANAVEX 2-73, a Mixed Muscarinic Cholinergic...
Nov 11, 2013
Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013
Nov 7, 2013
Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of AD
Nov 4, 2013
Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting
Oct 28, 2013
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73
Oct 21, 2013
Anavex Comments on Newly Released World Alzheimer Report 2013
Sep 22, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
Sep 2, 2013
Anavex CEO Writes Letter to Shareholders
Aug 14, 2013
Anavex Raises $2.6M in Private Placement and Conversion of Liabilities, Enters into $10M Financing
Jul 7, 2013
42
43
44
45
46
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
